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Abstract Of the numerous gaseous substances that can act
as signaling molecules, the best characterized are nitric
oxide, carbon monoxide and hydrogen sulfide. Contribu-
tions of each of these low molecular weight substances,
alone or in combination, to maintenance of gastrointestinal
mucosal integrity have been established. There is consid-
erable overlap in the actions of these gases in modulating
mucosal defense and responses to injury, and in some
instances they act in a cooperative manner. Each also play
important roles in regulating inflammatory and repair
processes throughout the gastrointestinal tract. In recent
years, significant progress has been made in the develop-
ment of novel anti-inflammatory and cytoprotective drugs
that exploit the beneficial activities of one or more of these
gaseous mediators.
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Introduction
The gastrointestinal (GI) tract shows a remarkable resi-
lience to damage induced by the beverages and foods that
we ingest, which can have a wide range of osmolarity, pH
and temperature. It is rare for the GI mucosa to succumb,
in a clinically significant way, to the detergent actions of
bile, to the proteolytic actions of gastric, intestinal or
pancreatic secretions, to many of the different types of
drugs that we ingest, or to the potentially harmful actions
of certain enteric microbes colonizing the GI tract [1].
This resistance to tissue damage is collectively referred to
as ‘‘mucosal defense’’ and it consists of a range of dif-
ferent factors that act to prevent injury and to promote
rapid repair when injury occurs. In recent years, we have
come to a better understanding of the mechanisms
underlying GI mucosal defense, as well as the systems for
rapid and orderly repair of damage. Intertwined with
these is the crucial role of inflammation as a predomi-
nantly beneficial process that can become detrimental
when dysregulated. Such dysregulation can be triggered
by certain drugs or infections. Many different chemical
mediators participate in mucosal defense, inflammation
and repair. In this paper, we describe some of the key
components of GI mucosal defense and the evidence for
significant roles of three gaseous mediators in GI mucosal
defense (nitric oxide (NO), hydrogen sulfide (H2S) and
carbon monoxide (CO)) in modulating the various ele-
ments of mucosal defense. We also discuss the potential
for drug development based on these gaseous mediators
that is specifically related to enhancement of GI mucosal
defense, anti-inflammatory activity and/or promotion of
healing.
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Gaseous Mediators of GI Mucosal Defense
NO is the most studied of the three gaseous mediators.
Numerous drugs have been developed for which the release
of NO accounts for a significant part of their actions,
including nitroglycerin. The 1998 Nobel Prize for Physi-
ology/Medicine was awarded for the discovery that NO
accounted for the vasodilatory actions that had previously
been attributed to ‘endothelium-derived relaxing factor’
[2]. NO is produced by many different types of cells in the
GI tract and performs a wide range of functions that
include many pertinent to GI mucosal defense (see below).
There are three enzymes primarily responsible for NO
production: NOS-1 (‘‘neuronal’’), NOS-2 (‘‘inducible’’)
and NOS-3 (‘‘endothelial’’) (Fig. 1). NOS-1 and NOS-3 are
generally regarded as being constitutively expressed,
though their expression can be modulated [2].
H2S has long been known as a potentially toxic gas with
a pungent smell, but studies by Kimura and Abe in 1996
[3, 4] and Wang et al. in 2001 [5] drew attention to
physiological roles of this molecule in the nervous and
circulatory systems, respectively. These studies stimulated
a burst of research into the role of this gaseous mediator in
many cells, tissues and organs, and suggested several
potential clinical applications for drugs that deliver H2S or
inhibit synthesis of H2S [6]. There are several enzymatic
pathways for H2S synthesis in eukaryotes (Fig. 1).
H2S is implicated in the origin of life, and served as a
major energy source for organisms for most of the time
since then (oxygen replaced H2S as the major energy
source only in the last *600 million years) [7]. Interest-
ingly, mitochondria can utilize H2S to drive adenosine
triphosphate (ATP) production. In mammals, the cells that
are most efficient at H2S-driven energy production are the
epithelial cells lining the GI tract [8, 9].
Like H2S, CO is known primarily as a pollutant, but in
the past two decades its role as a gaseous mediator in
many biological processes have become clear [10]. Pro-
duction of CO from heme occurs via the enzyme
hemoxygenase-1 (HO-1; constitutive) and hemoxygenase-
2 (HO-2; inducible) (Fig. 1). Most current literature with
respect to the GI tract is focused on CO derived from HO-
1, which is constitutively expressed in many types of cells
in the GI tract, including epithelial cells, mononuclear
cells, endothelial cells, and smooth muscle [11]. Bili-
verdin is the other product of this reaction. The metabo-
lism of heme, through the actions of HO-1, has beneficial
effects (e.g., reduction of oxidative stress) since heme can
be cytotoxic. HO-2 in the GI tract is primarily involved in
modulating smooth muscle membrane potential and neu-
romodulation [12] CO also acts as a signaling molecule,
influencing a wide range of biological processes and
exerting cytoprotective and anti-inflammatory effects
[11]. CO is much more biologically stable than NO and
H2S since it is not a free radical. Thus, unlike the other
two gaseous mediators, it is able to produce effects distant
to where it is produced [13].
A significant limitation for exploring the effects of CO
in vivo has been the lack of a range of CO donors that are
proven to be useful for experimental studies. The most
useful tools available thus far have been a group of
molecules called ‘‘CORMs’’ (CO-releasing molecules),
developed by Motterlini and colleagues [10]. Some bene-
ficial effects of CORMs appear to be due to down-regu-
lation of expression of NOS2 [14], an example of cross-talk
among the gaseous mediators.
Fig. 1 Pathways of synthesis of three gasotransmitters (hydrogen
sulfide, carbon monoxide and nitric oxide; H2S, CO and NO,
respectively). H2S can be produced from L-cysteine through three
separate pathways. Cystathionine gamma-lyase (CSE) and cystathion-
ine ß-synthase (CBS) are widely expressed and considered the major
enzymatic courses of H2S, producing pyruvate and L-serine as by-
products, respectively. The sequential actions of cysteine aminotrans-
ferase (producing 3-mercaptopyruvate from L-cysteine) and 3-mer-
captopyruvate sulfurtransferase (3MST) can also produce H2S. A
fourth pathway of H2S synthesis, not shown, is that from D-cysteine
via the enzymes 3MST and D-amino acid oxidase [88]. CO is
produced from heme via the actions of hemoxygenase-1 (HO-1;
constitutively expressed) or hemoxygenase-2 (HO-2; inducible
expression), with biliverdin and iron produced as by-products of this
reaction. NO can be produced from L-arginine and NADPH by three
forms of NO synthase, yielding L-citrulline as a by-product. NOS1
and NOS 3 are constitutively expressed, while NOS2 is inducible. The
three NOS isoforms were previously known as neuronal NOS
(NOS1), inducible NOS (NOS2) and endothelial NOS (NOS3)
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Mucus and Bicarbonate Secretion
Mucus is secreted by GI epithelial cells and goblet cells,
and acts as a lubricant to reduce physical abrasion of the
mucosa. It also plays important roles in protection of the
mucosa from damage induced by acid and other luminal
toxins. It provides an important physical barrier to bacteria,
reducing bacterial adherence to the epithelium and thereby
reducing translocation into the lamina propria.
An increase in mucus thickness is a normal defensive
response to luminal insults. As well as providing a barrier
to translocation of microbes into the sub-epithelial space,
mucus traps secreted bicarbonate and plasma on the sur-
face of the epithelium, which provides a near-neutral pH
microenvironment that is conducive to epithelial protec-
tion and repair. All three gaseous mediators can influence
mucus secretion in the GI tract. NO stimulates epithelial
mucus secretion via activation of guanylyl cyclase in
epithelial cells [15], and carbachol-induced gastric mucus
release is also mediated via NO [16]. H2S and CO can
also increase gastric mucus secretion [17–19]. The effects
of H2S on colonic mucus secretion are particularly
interesting and complex. In healthy rats, microbiota form
linear biofilms in the colon. During colitis, the biofilms
become fragmented, and production of mucus granules is
markedly reduced [19]. Endogenous H2S production
stimulates mucus production and promotes establishment
of microbiota biofilms. Moreover, administration of an
H2S donor to rats with colitis restores the microbiota
biofilm as well as increasing the production of mucus by
the epithelium [19].
The GI epithelium also defends itself against bacterial
invasion via the secretion of fluid into the lumen. This
reduces bacterial adherence, and the secretion of fluid also
dilutes any noxious substances in the lumen. Fluid secre-
tion across the GI epithelium is mainly osmotically driven
by the active transport of chloride ions into the lumen. This
process is regulated by numerous soluble mediators and
neurotransmitters, including NO [20]. NO donors can
stimulate chloride transport in the small intestine [21, 22].
However, the effects of NO on intestinal secretion are not
always stimulatory: low concentrations of NO are stimu-
latory while high concentrations are inhibitory. NO also
plays a key role in some of the long-term impairment of
epithelial secretion that can be observed after a bout of
intestinal inflammation. [23, 24].
Secretion of bicarbonate by gastric and duodenal
epithelial cells is a very important component of mucosal
defense, and it can be significantly modulated by the three
gaseous mediators [25]. In the resting state, there is a basal
level of gastroduodenal bicarbonate secretion, but a sig-
nificant increase is triggered when acid back-diffuses into
the mucosa. All three of the gaseous mediators can stim-
ulate bicarbonate secretion [26, 27]. Thus, duodenal
bicarbonate secretion is increased after administration of an
H2S donor, and diminished by an inhibitor of endogenous
H2S synthesis. Suppression of H2S synthesis also leads to
an enhancement of acid-induced duodenal damage [25].
Administration of an H2S-releasing derivative of naproxen
(ATB-346) resulted in a marked (*50%) decrease in
gastric acidity, with the mean pH of gastric juice increasing
from 1.5 to 2.1, and a[80% decrease in the volume of
secretion [28]. Similar results were reported from studies
using another H2S donor [29]. The decrease in gastric
acidity observed after administration of an H2S donor did
not appear to be due to suppression of acid secretion
[17, 28]. Regulation of bicarbonate and acid secretion by
H2S may contribute significantly to the gastroprotective
effects of H2S-releasing NSAIDs [28].
With respect to CO, administration of CORM-2 dose-
dependently stimulated duodenal bicarbonate secretion
[26]. Suppression of NO synthesis did not affect this
response, but suppression of cyclooxygenase (COX)
activity significantly attenuated CO-stimulated bicarbonate
secretion, suggesting a role for prostanoids in mediating the
effects of CO. Exposure of the duodenal mucosa to acid
resulted in a significant increase in expression of HO-1, but
not HO-2 [26].
Acid-induced duodenal bicarbonate secretion is also
mediated in part via local release of NO and via generation
of prostaglandins [27]. Indeed, both guanylin, an endoge-
nous activator of guanylate cyclase, and NOR-3, a NO
donor, increased bicarbonate secretion [27].
Acid Secretion
Gastric acid is a defensive factor in that it is bactericidal. The
importance of acid in this regard is evident from studies
demonstrating that marked suppression of acid secretion
results in increased bacterial colonization of the stomach
[30]. Moreover, suppression of gastric acid secretion can
lead to dramatic, biologically significant alterations in the
small intestinal microbiota, increasing the risk of enteric
infection [31] and contributing to several disorders, includ-
ing microscopic colitis, inflammatory bowel disease and
small intestinal bacterial overgrowth [32–34]. For example,
administration of proton pump inhibitors or histamine H2
receptor antagonists, prescribed with a primary goal of
reducing NSAID-induced upper GI damage, markedly
increase the severity of small intestinal damage [35–38].
Studies in laboratory animals demonstrated that treatment
with a proton pump inhibitor led to a marked depletion of
Actinobacteria and Bifidobacteria species in the small
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intestine [35], and this was accompanied by significant
increases in the cytotoxicity of bile [39, 40]. Replenishment
of intestinal Bifidobacteria levels restored to normal the
intestinal resistance to NSAID-induced injury [35].
The three gaseous mediators have minimal effects on
gastric acid secretion [17, 41, 42].
Mucosal Blood Flow and Microcirculation
Regulation of blood flow is critical to mucosal defense.
This is particularly so in the stomach and duodenum, where
back-diffusion of acid can cause extensive damage and
bleeding. However, a well-characterized and rapid reactive
hyperemic response to acid back-diffusion can prevent or
limit mucosal injury. This response is initiated by sensory
afferent nerves underlying the epithelium, which respond
immediately to entry of acid into the lamina propria [43].
Release of calcitonin gene-related peptide (CGRP) from
these neurons results in immediate dilation of submucosal
arterioles facilitating the dilution and buffering of the back-
diffused acid [44]. The CGRP vascular response is medi-
ated by NO; administration of an inhibitor of NO synthesis
abolishes the reactive hyperemic response, resulting in a
marked increase in the susceptibility of the mucosa to
damage [45]. There is strong evidence for CO and H2S
contributing significantly to maintenance of tissue perfu-
sion in the upper GI tract, particularly when acid back-
diffusion has been triggered by agents such as non-steroidal
anti-inflammatory drugs (NSAIDs) or ethanol [46–48].
The GI tract, particularly distal to the duodenum, is
essentially in a state of chronic, low-grade inflammation.
This is due to the ongoing interaction (and trans-epithelial
migration) of luminal bacteria and their products with the
mucosal immune system. Leukocytes can be stimulated to
extravasate from mucosal blood vessels by chemotaxins
that are released from bacteria, and this process can result
in damage to the blood vessels and surrounding tissue, and
further generation of chemotaxins. NO, H2S and CO all
play roles in modulating leukocyte adherence to the vas-
cular endothelium, and as discussed above, maintenance of
blood flow to the tissue. For example, inhibition of NO
synthesis results in a marked increase in leukocyte adher-
ence to the endothelium [49]. NO has been shown to inhibit
expression of the ß-2 adhesion molecules on neutrophils
[50] and P-selectin on the vascular endothelium [51].
Adherence of leukocytes to the vascular endothelium in
response to stimulation with a chemotactic factor can be
suppressed by administration of an NO donor [52]. Inhi-
bition of H2S synthesis can trigger leukocyte adherence to
the vascular endothelium, while H2S donors have inhibi-
tory effects on this process [53], as well as suppressing
leukocyte infiltration in models of inflammation [54]. CO
can also inhibit leukocyte adherence [55]. It has been
suggested that the reduction of mucosal injury elicited by
inducers of HO-1 occur as a consequence of inhibition of
leukocyte infiltration [56].
Cytoprotection
NO donors exert protective effects in the GI tract through a
range of mechanisms that include increasing mucosal
blood flow, inhibiting leukocyte adherence to the vascular
endothelium, and stimulating mucus and bicarbonate
secretion [57]. Some of the beneficial effects of NO may be
attributable to CO, since NO can induce heme oxygenase
[58]. NO-releasing NSAIDs demonstrated greatly reduced
damaging effects in the GI tract in extensive animal testing
and in early clinical trials [28]. However, in a pivotal trial
of an NO-releasing derivative of naproxen, a statistically
significant reduction of upper GI damage was not achieved
[59].
Like NO, H2S has been shown to be cytoprotective for
the GI tract in animal studies [60]. For H2S, there is con-
siderable overlap with NO in terms of the protection
afforded by H2S donors and the exacerbation of damage
with drugs that suppress H2S synthesis [47, 48]. An H2S-
releasing NSAID has been shown to be very effective and
potent in reducing osteoarthritis-related pain [61] and
recently a phase 2 clinical trial to examine its safety in the
GI tract was initiated.
HO-1 and CO have been shown to exert beneficial
effects in animal models of gastric ulceration, including
NSAID-induced mucosal injury [16, 48, 62, 63] and the
enteropathy associated with post-operative ileus [64]. CO
has also been observed to protect the stomach from etha-
nol-induced lesions, mediated in part by NO and by COX-
1-derived prostaglandin synthesis [49].
Healing and Resolution of Inflammation
Given the many potentially damaging substances present in
the lumen of the GI tract, mechanisms to resist damage are
backed up by mechanisms for rapid repair when damage
occurs. The gaseous mediators participate significantly in
these repair processes. Inhibitors of NO or H2S synthesis
significantly retard gastric ulcer healing and healing of
damaged tissue in models of colitis [65–69]. On the other
hand, NO, CO and H2S donors accelerate the healing of
these lesions [66–68, 70]. The pro-healing effects of these
gases are mediated in part by increased epithelial cell
migration and proliferation, and through enhancement of
collagen deposition by fibroblasts [67, 68, 70, 71]. Another
mechanism through which these vasodilatory gases can
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accelerate ulcer healing is via maintenance of blood flow at
the margin of the wound. Ulcer healing requires prolifer-
ation and differentiation of epithelial cells at the ulcer
margin, and that in turn is dependent upon adequate blood
flow—reductions of blood flow in these circumstances
result in a retardation of ulcer healing [72]. Ulcer healing
also requires the growth of new blood vessels in the ulcer
margin, through the process of angiogenesis, and all three
of the gaseous mediators are stimulants of this process [73].
The anti-inflammatory and pro-resolution effects of the
gaseous mediators are also evident in the more distal GI
tract, particularly in colitis. H2S has been shown to play an
important role in regulating prostaglandin synthesis and
expression of COX-2 in the GI tract [68] (Fig. 2). This has
a significant impact on maintenance of mucosal integrity
and the capacity to rapidly respond to injury. Thus, H2S
promotes the expression of COX-2 in the GI tract, while
inhibitors of H2S synthesis reduce this ‘‘constitutive’’
expression of COX-2 [68]. However, when there is chronic
inflammation, such as in colitis, H2S can dampen COX-2
expression, leading to reduced levels of several pro-in-
flammatory cytokines and chemokines [52, 68, 69, 74].
Thus, H2S plays important roles in promoting resolution of
inflammation in the GI tract [19, 52, 69, 74]. H2S synthesis
is specifically up-regulated at sites of ulceration in the
colon, and degradation of H2S is down-regulated; thus,
levels of H2S increased in ulcerated tissue, where rapid
healing is most needed [69]. Inhibition of H2S synthesis in
models of colitis results in a marked exacerbation of
damage and delay of healing [68, 74].
H2S is unique among the three major gaseous mediators
in that it can substitute for oxygen in driving the generation
of ATP in mitochondria. Thus, H2S acts as a ‘rescue
molecule’ in many circumstances, helping to preserve tis-
sue integrity and function while repair occurs. The
epithelial cells of the GI tract have been reported to be the
most efficient at using H2S to drive mitochondrial ATP
production [8, 9, 75]. The efficient oxidation of bacteria-
derived H2S by the intestinal epithelium is also a means of
limiting H2S from entry to the mucosa [8, 9, 75];
Fig. 2 Interactions of hydrogen sulfide (H2S) and cyclooxygenase-2
(COX-2) regulate gastrointestinal (GI) mucosal defense, inflammation
and repair. In healthy rats (panel A) there is low-grade inflammation
in the GI tract, and constitutive H2S synthesis stimulates ‘basal’
COX-2 expression, and synthesis of prostaglandins (PG) that
contribute to mucosal defense and repair. Panels B and C: pharma-
cological inhibition of H2S synthesis with ß-cyanoalanine (BCA)
results in a significant reduction of COX-2 expression and
prostaglandin E2 synthesis in the GI tract, as well as significant
increases in tissue granulocyte numbers (p\ 0.05 versus vehicle-
treated). Thus, suppression of H2S synthesis removes a basal
cytoprotective factor, which results in impaired mucosal defense
and chronic injury and inflammation [89]
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nevertheless, approximately half of the H2S that can be
measured in the body is derived from bacteria [76, 77].
The role of NO in treatment and pathogenesis of IBD is
very complicated, with some studies showing beneficial
effects of treatment with NO donors [52, 78] and others
showing beneficial effects of inhibition of endogenous NO
synthesis [79, 80]. Expression and activity of NOS2 are
markedly increased in colitis and appear to drive inflam-
mation and, in particular, expression of pro-inflammatory
cytokines [81]. Selective suppression of NOS2 activity has
been shown to promote resolution of intestinal inflamma-
tion [79, 80]. However, other studies suggest that NO
derived from NOS2 drives resolution of colitis [82] and is
also responsible for long-lasting impairment of intestinal
secretory function, which may underlie post-inflammatory
gut dysfunction [23, 24]. It is likely that much of this
discrepancy of results and conclusions in the literature is
attributable to ‘off-target’ effects of the pharmacological
tools that have been used, and variable responses of the
many different animal models that have been employed.
Administration of CORM-2 [83] or CO given via
inhalation [84] have also been shown to produce beneficial
effects in experimental colitis, including marked reductions
in pro-inflammatory cytokine expression, granulocyte
infiltration, crypt damage and ulcers [83, 84]. The reduc-
tion of pro-inflammatory cytokine expression may be
attributable to CO-induced inhibition of NF-jB activity
[84, 85]. CO derived from HO-1 may also ameliorate
intestinal inflammation by promoting the clearance of
bacteria at sites of injury [86]. Innate immune cells
exposed to CO have been shown to have enhanced bacte-
ricidal activity [86]. Interestingly, there are enteric bacte-
rial hemoxygenase homologs that may serve as a
significant source of CO in the GI tract, possibly playing a
role in promotion of homeostasis [86].
Future Directions
There is an extensive body of work demonstrating impor-
tant roles of NO, H2S and CO in modulating a wide range
of physiological processes, and suggesting their utility as
therapeutics. With respect to the GI tract, there are many
potential clinical applications for gaseous mediators if they
can be delivered to the target tissues in appropriate
amounts. Most of the evidence that has been generated thus
far suggest important roles for these gaseous mediators in
promoting GI tissue integrity, modulation of inflammation
and acceleration of tissue repair. Evidence that H2S donors
can modify the intestinal microbiome, in a positive manner,
is particularly intriguing [19, 39, 40]. A limitation of most
studies of gaseous mediators in the GI tract is that very
simple donor molecules have been used that release the
mediator but in an uncontrolled and non-targeted manner.
The future of this field with respect to drug development
will require patented molecules that will release the gas-
eous mediator at a rate appropriate for promoting health,
and at the specific locations where the effects of the
mediator are most needed. This will be a significant chal-
lenge, but there have been some successful developments
in recent years, one example being H2S donors that
specifically target mitochondria [87].
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